USO 24279
A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
Disease Types: Solid Tumors Research
Eligibility Requirements:
Signed informed consent
Adult men and women ≥18 years of age
Participants must have histologically confirmed, locally advanced or metastatic NeuroEndocrine Carcionomas (NEC), and must have experienced disease progression on or after platinum-based therapy
Participants must be willing to undergo a tumor biopsy or must provide archived tumor tissue sample
Participants must have at least one measurable target lesion as defined by RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy ≥ 3 months
For more information on this trial CLICK HERE .
Available at: